Cargando…
SAT035 Oligonucleotide IMT504 Markedly Improves Metabolic Sindrome And Type 2 Diabetes In High-Fat Diet Fed Mice
Disclosure: L. Domé: None. J.M. Riaño Gomez: None. M.M. Bonaventura: None. M.O. Fernandez: None. A.D. Montaner: None. V.A. Lux-Lantos: None. M.S. Bianchi: None. We have shown that the immunomodulatory oligonucleotide IMT504 (IMT) improves glucose homeostasis in several animal models of type 1 diabet...
Autores principales: | Domé, Laila, Riaño Gomez, Juan Manuel, Marta Bonaventura, María, Olga Fernandez, Marina, Daniel Montaner, Alejandro, Adela Lux-Lantos, Victoria, Silvia Bianchi, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555959/ http://dx.doi.org/10.1210/jendso/bvad114.903 |
Ejemplares similares
-
SAT-172 Continuous, Prolonged Treatment with the Oligonucleotide IMT504 in Diabetic NOD Mice Greatly Improves All Parameters of the Diabetic Condition
por: Bianchi, Stefania, et al.
Publicado: (2019) -
SAT-165 Does Oligodeoxynucleotide IMT504 Have Any Effect On Beta Cells? A Preliminary Study On MIN6B1 Cell Line
por: Converti, Ayelén, et al.
Publicado: (2019) -
IMT504 protects beta cells against apoptosis and maintains beta cell identity, without modifying proliferation
por: Converti, Ayelén, et al.
Publicado: (2023) -
Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy
por: Zorzopulos, Jorge, et al.
Publicado: (2017) -
LBODP035 When Is Ketosis Just Ketosis?
por: Cannon, Sophie M, et al.
Publicado: (2022)